Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Hepatology ; 58(1): 108-19, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23408358

RESUMEN

UNLABELLED: The intestinal mucus layer protects the epithelium from noxious agents, viruses, and pathogenic bacteria present in the gastrointestinal tract. It is composed of mucins, predominantly mucin (Muc) 2, secreted by goblet cells of the intestine. Experimental alcoholic liver disease requires translocation of bacterial products across the intestinal barrier into the systemic circulation, which induces an inflammatory response in the liver and contributes to steatohepatitis. We investigated the roles of the intestinal mucus layer, and in particular Muc2, in development of experimental alcohol-associated liver disease in mice. We studied experimental alcohol-induced liver disease, induced by the Tsukamoto-French method (which involves continuous intragastric feeding of an isocaloric diet or alcohol) in wild-type and Muc2(-/-) mice. Muc2(-/-) mice showed less alcohol-induced liver injury and steatosis than developed in wild-type mice. Most notably, Muc2(-/-) mice had significantly lower plasma levels of lipopolysaccharide than wild-type mice after alcohol feeding. In contrast to wild-type mice, Muc2(-/-) mice were protected from alcohol-associated microbiome changes that are dependent on intestinal mucins. The antimicrobial proteins regenerating islet-derived 3 beta and gamma were expressed at significantly higher levels in the jejunum of Muc2(-/-) mice fed the isocaloric diet or alcohol compared with wild-type mice. Consequently, Muc2(-/-) mice showed increased killing of commensal bacteria and prevented intestinal bacterial overgrowth. CONCLUSION: Muc2(-/-) mice are protected from intestinal bacterial overgrowth and dysbiosis in response to alcohol feeding. Subsequently, lower amounts of bacterial products such as endotoxin translocate into the systemic circulation, decreasing liver disease.


Asunto(s)
Hepatopatías Alcohólicas/genética , Mucina 2/deficiencia , Alcoholismo/patología , Animales , Modelos Animales de Enfermedad , Etanol/metabolismo , Hígado Graso/etiología , Hígado Graso/genética , Humanos , Absorción Intestinal/genética , Mucosa Intestinal/patología , Intestinos/microbiología , Lipopolisacáridos/sangre , Hígado/metabolismo , Hepatopatías Alcohólicas/etiología , Masculino , Ratones , Ratones Endogámicos C57BL , Mucina 2/fisiología
2.
Nat Commun ; 11(1): 5099, 2020 10 09.
Artículo en Inglés | MEDLINE | ID: mdl-33037202

RESUMEN

Mutations in the skeletal muscle Ca2+ release channel, the type 1 ryanodine receptor (RYR1), cause malignant hyperthermia susceptibility (MHS) and a life-threatening sensitivity to heat, which is most severe in children. Mice with an MHS-associated mutation in Ryr1 (Y524S, YS) display lethal muscle contractures in response to heat. Here we show that the heat response in the YS mice is exacerbated by brown fat adaptive thermogenesis. In addition, the YS mice have more brown adipose tissue thermogenic capacity than their littermate controls. Blood lactate levels are elevated in both heat-sensitive MHS patients with RYR1 mutations and YS mice due to Ca2+ driven increases in muscle metabolism. Lactate increases brown adipogenesis in both mouse and human brown preadipocytes. This study suggests that simple lifestyle modifications such as avoiding extreme temperatures and maintaining thermoneutrality could decrease the risk of life-threatening responses to heat and exercise in individuals with RYR1 pathogenic variants.


Asunto(s)
Hipertermia Maligna/genética , Mutación , Canal Liberador de Calcio Receptor de Rianodina/genética , Termogénesis/fisiología , Tejido Adiposo Pardo/metabolismo , Adolescente , Adulto , Animales , Niño , Preescolar , Femenino , Respuesta al Choque Térmico/genética , Respuesta al Choque Térmico/fisiología , Humanos , Lactante , Lactatos/sangre , Masculino , Hipertermia Maligna/etiología , Hipertermia Maligna/mortalidad , Ratones Endogámicos C57BL , Ratones Noqueados , Persona de Mediana Edad , Estudios Retrospectivos , Canal Liberador de Calcio Receptor de Rianodina/metabolismo , Termogénesis/genética , Proteína Desacopladora 1/genética , Adulto Joven
3.
Nat Cardiovasc Res ; 1(11): 973-975, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-39195909
4.
Nat Commun ; 8(1): 2137, 2017 12 12.
Artículo en Inglés | MEDLINE | ID: mdl-29233961

RESUMEN

In the original PDF version of this Article, which was published on 16 October 2017, the publication date was incorrectly given as 10 October 2017. This has now been corrected in the PDF; the HTML version of the paper was correct from the time of publication.

5.
Nat Commun ; 8(1): 837, 2017 10 16.
Artículo en Inglés | MEDLINE | ID: mdl-29038503

RESUMEN

Chronic liver disease is rising in western countries and liver cirrhosis is the 12th leading cause of death worldwide. Simultaneously, use of gastric acid suppressive medications is increasing. Here, we show that proton pump inhibitors promote progression of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis in mice by increasing numbers of intestinal Enterococcus spp. Translocating enterococci lead to hepatic inflammation and hepatocyte death. Expansion of intestinal Enterococcus faecalis is sufficient to exacerbate ethanol-induced liver disease in mice. Proton pump inhibitor use increases the risk of developing alcoholic liver disease among alcohol-dependent patients. Reduction of gastric acid secretion therefore appears to promote overgrowth of intestinal Enterococcus, which promotes liver disease, based on data from mouse models and humans. Recent increases in the use of gastric acid-suppressive medications might contribute to the increasing incidence of chronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secretion and modulate gut microbiota composition. Here Llorente et al. show that PPIs induce bacterial overgrowth of enterococci, which, in turn, exacerbate ethanol-induced liver disease both in mice and humans.


Asunto(s)
Ácido Gástrico/fisiología , Hepatopatías Alcohólicas/patología , Microbiota/efectos de los fármacos , Enfermedad del Hígado Graso no Alcohólico/patología , Inhibidores de la Bomba de Protones/efectos adversos , Animales , Progresión de la Enfermedad , Enterococcus/efectos de los fármacos , Enterococcus/crecimiento & desarrollo , Femenino , Humanos , Incidencia , Hepatopatías Alcohólicas/epidemiología , Masculino , Ratones , Ratones Endogámicos C57BL , Enfermedad del Hígado Graso no Alcohólico/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA